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Abstract
The involvement of noncoding RNAs (ncRNAs) in the development of the human brain remains largely unknown. Applying
a cloning strategy for detection of intermediate size (50–500 nt) ncRNAs (is-ncRNAs) we have identified 82 novel transcripts
in human fetal brain tissue. Most of the novel is-ncRNAs are not well conserved in vertebrates, and several transcripts were
only found in primates. Northern blot and microarray analysis indicated considerable variation in expression across human
fetal brain development stages and fetal tissues for both novel and known is-ncRNAs. Expression of several of the novel is-
ncRNAs was conspicuously absent in one or two brain cancer cell lines, and transient overexpression of some transcripts in
cancer cells significantly inhibited cell proliferation. Overall, our results suggest that is-ncRNAs play important roles in the
development and tumorigenesis of human brain.
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Introduction
It is increasingly becoming evident that a major part of the
information content in eukaryote genomes is expressed in the form
of non-protein-coding RNAs (ncRNAs; [1]). The advancements in
the ncRNA field, including the discovery of novel classes of
ncRNA as well as new members of existing classes, steadily expand
our understanding of ncRNA function. NcRNAs have been
demonstrated to act as key regulators in most aspects of cellular
and developmental biology, including embryonic development,
cell differentiation and tumorigenesis [2,3,4].
A variety of different noncoding transcripts are involved in
development and function of the vertebrate central nervous system
[5]. MicroRNAs remain the most intensively investigated
noncoding segment, and a number of brain specific miRNAs
with distinct functions have been investigated [6]. Some micro-
RNAs are highly expressed in vertebrate neural tissues [7], and
Dicer mutants in mice and zebrafish show various neurological
phenotypes [8,9]. In worm and fly model organisms miRNAs
decide neuron sensory asymmetry [10] and regulate sensory organ
development by specifying the generation of neuronal precursor
cells [11]. MicroRNAs have also been associated with a several
neurodegenerative diseases such as Alzheimers’ dementia [12,13],
Huntington’s disease [14], and glioblastoma [15].
Despite the intense focus on miRNAs in recents years, these
transcripts represent only a fraction of the entire non-protein coding
transcriptional output from mammalian genomes. Far less attention
has been directed at the possible involvement of other ncRNAs on
brain development and function. Nonetheless, analysis of pig
noncoding EST (expressed sequence tag) expression patterns
indicated a higher frequency of candidate ncRNAs being expressed
in central nervous system relative to other tissues; in contrast, the
testis showed a high number of expressed protein coding genes, but
a relative lownumberofnon-coding transcripts[16].Inthemousea
high number of longer ncRNAs are expressed inthe centralnervous
system [17]. The conserved ncRNA TUG1 is expressed in the eye,
brain and a few other tissues, and is required for photoreceptor
development in the mouse [18]. The brain cortex expressed HAR1F
and HAR1R transcripts originate from a locus that is highly
conserved in all mammals, including the chimpanzee, but show
distinct differences in primary sequence and secondary structure in
human [19]. The maternally expressed ncRNA Meg3/Gtl2 is
expressed in the mouse brain, inner ear and eye, displaying
differently spliced isoforms in the different tissues [20], and in
response to infection by several encephalitic viruses the 3.2 kb
noncoding VINC locus is expressed in the mouse brain [21].
There are fewer examples of involvement of intermediate size
(i.e., 50–500 nt) ncRNAs in neuronal processes. A few small
nucleolar RNAs are exclusively expressed in mouse and rat brain
[22,23]. Homologues to three of the mouse loci map to the human
chromosomal region 15q11-q13, which contains a large number of
tandemly repeated C/D box snoRNA loci with paternal imprinted
expression [22]. This chromosomal region is implicated in the
neurogenetic Prader-Willi syndrome (PWS) [22], and detailed
analysis suggests the PWCR1/HBII-85 snoRNA cluster and the
single HBII-438A snoRNA as the most likely candidate loci
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21652involved in the syndrome [23]. The rat C/D box snoRNA RBII-
36 locus is situated within an intron of the noncoding RNA Bsr,
and appears to be generated from both debranched intron-lariats
as well as from endonucleolytic cleavage of the Bsr primary
transcript [24]. Another example of intermediate-size brain
specific noncoding RNAs are the BC1 and BC200 transcripts
found in rodents and primates, respectively. These transcripts have
cytoplasmic neuronal expression patterns, including a concentra-
tion to dendrites [25,26] and axons [27]. Both RNAs bind to
several proteins involved mRNA translation [28,29,30], and their
expression appear to depend on neuronal activity [31]. Knock-out
BC1 mice do nonetheless develop normally, but show signs of
increased anxiety [32].
In the present study, we report a systematic identification and
validation of 82 novel intermediate-size ncRNAs (is-ncRNAs) from
human fetal brain. These novel is-ncRNAs are generally not well
conserved in vertebrates, and several loci are only found in
primates. Northern blot and microarray analysis indicated
considerable variation in is-ncRNA expression across fetal tissues
and fetal brain development stages, and expression of several novel
is-ncRNAs were dramatically decreased in one or two brain tumor
cell lines. Moreover, transient overexpression of some is-ncRNAs
in SH-SY5Y cells significantly affected cell vitality and prolifer-
ation. Altogether, our results provide new insights into the
diversity of is-ncRNAs and their involvement in brain develop-
ment and tumorigenesis.
Results
ncRNA-specific library
To discover novel human ncRNAs , we used a previously
described strategy [33] to construct a ncRNA-specific full length
library from human fetal brain. Intermediate size ncRNAs (50–
500 nt) were extracted from human fetal brain tissue, cloned and
sequenced (Materials and Methods). A computational pipeline was
developed to process the sequencing data and to distinguish novel
ncRNA candidates from known classes of small RNAs. Removal
of sequences that represented annotated mRNAs, rRNAs and
tRNAs from the altogether 20,539 sequenced clones left 17,723
transcripts corresponding to 326 unique sequences which could be
mapped to 331 loci in the human genome (Figure 1A; Figure S1;
Table S1). The majority of these (244 unique sequences or 249
loci) corresponded to known or predicted (henceforth referred to
as ‘‘known’’) is-ncRNA genes of various classes, whereas 82 unique
sequences/loci did not map to any annotated gene, and were
consequently considered as potential novel ncRNA candidates
(Figure 1B). The majority of these 82 unique sequences were
identified by a single clone, and may represent RNA species that
function at low copy number or in only a limited number of cell
types. Northern blot or RT-PCR analyses gave positive signals for
all of the 82 sequences in brain tissue (Figure 2; Figure S2 and S3).
Genomic location of the novel ncRNAs
Mapping the genomic loci of the 82 novel ncRNAs revealed no
significant deviation from a random chromomal distribution
(Table S2). There were 27 intergenic loci, 44 and 11 loci that
located in sense or antisense orientation, respectively, to introns of
protein-coding genes, and the host genes of the 44 sense intronic
loci were analysed for enrichment of annotated gene ontology
(GO; [34]) or cellular pathway (KEGG; [34]) terms. No GO
function term was statistically enriched among the host genes;
however, four of the 44 host genes belong to the ‘Axon Guidance’
pathway (p-value=4.04610
24; details concerning host gene
annotation and position in the pathway are found in Table S3).
Of the corresponding four ncRNAs, nc068 showed a ‘brain and
heart specific’ expression pattern (Figure 2A). Two of the ncRNAs
(nc012 and nc026) also displayed developmentally related changes
in fetal brain expression (Figure 2E). As no sequence homology
extending 10 bp was found between any of these four ncRNAs
and the coding regions of their respective host genes, any potential
co-regulatory relationships between the ncRNAs and their host
genes is probably not based on extensive Watson-Crick base-
pairing.
Several of the novel ncRNA loci overlap loci annotated as
‘‘noncoding’’, and may represent active loci with sequence or
secondary characteristics that deviate from what is commonly
found in the human or other mammalian genomes. Potential
snoRNA and scaRNA candidates were identified by applying the
snoScan/snoGPS, snoSeeker, and snoReport software [35] to the
longest sequence read from each locus. Fourteen transcripts with
clear snoRNA or scaRNA characteristics were identified (Table
S4), of which four were identified as C/D box snoRNAs, nine
were H/ACA box snoRNAs, and one transcript (nc082) which
showed both C/D box and H/ACA box characteristics is a likely
scaRNA candidate.
Figure 1. Distribution of sequenced clones and is-ncRNA loci. (A) Distribution of sequenced clones. The segment denoted as ‘‘novel ncRNAs’’
refers to previously unreported transcripts. (B) Distribution of genetic loci corresponding to the detected is-ncRNAs.
doi:10.1371/journal.pone.0021652.g001
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To assess the conservation level of the 82 novel is-ncRNAs we
utilized the 28-way vertebrate sequence alignment by Miller [36],
but restricted our analysis to the 18 species (including human) with
a more than five-fold overall sequence coverage. As strongly
conserved ncRNA loci would already have been detected by
sequence comparisons, it was expected that most of the novel
candidate loci would show limited sequence conservation. In
accordance with this expectation, only 5 of the novel loci were
conserved beyond eutherian mammals (Figure 3). This group
nonetheless contained two of eight transcripts (nc018 and nc055)
with predominant expression in the fetal brain, suggesting a link
between is-ncRNAs and central nervous system development
extending all the way back to the fish.
The majority of the novel is-ncRNA loci could be broadly
clustered into three groups based on similar conservation charac-
teristics (Figure 3). The largest group contains 31 loci that are
conserved in most eutherian mammals, but not beyond these. Most
of these show strong conservation (average PhastCons score .0.8)
only in primates, and only two loci are strongly conserved
throughout eutherian Mammalia. Both of these display strong tissue
specific expressional characteristics; nc050 having distinctly elevated
expression in liver and heart, and nc013 being conspicuously absent
in two (liver and thymus) of eight analysed tissues (Figure 2). An
additional point of note is that most of the novel ncRNA loci tend to
be more strongly conserved in the cat, horse and dog than in the
rodent genomes.
A second cluster is composed of 22 loci that are conserved in
primates and most non-rodent mammals, but not in mouse or rat.
This is a peculiar conservation pattern given that recent
phylogenies [36] place rodents closer to the primate branch than
for instance the carnivores (although not without debate [37]), and
Figure 2. Expression of novel is-ncRNAs in human fetal tissues. (A) Relative expression of 82 novel is-ncRNAs extracted from human fetal
brain tissue as analysed by microarray. The leftmost column (shades of blue) shows the expression levels of different novel ncRNAs in fetal brain
tissue relative to the average expression in this tissue. The five columns to the right (shades of green) show the expression of each novel ncRNA
relative to its expression in fetal brain. (B) Relationship between conservation and expressional variation among fetal tissues. The figure shows
PhastCons scores plotted against maximal expressional variation among fetal tissues of known (red) and novel (blue) is-ncRNAs. (C) Northern blot of
the novel is-ncRNA nc013. Note the lack of expression in liver and thymus. (D) Northern blot analysis of 6 novel transcripts with predominant or
unique expression in the human fetal brain. (E) Relative expression of 82 novel is-ncRNAs in human fetal brain during four gestation stages. The
leftmost column (shades of blue) shows the expression levels of different novel ncRNAs in fetal brain tissue at 13 weeks of gestation. The four
columns to the right (shades of green) show the expression of each novel ncRNA in fetal brain at gestation stages 14 weeks, 20 weeks and 24 weeks
relative to its expression at 13 weeks of gestation. (F) A magnified view from Figure E, which represents the relative expression of 7 novel is-ncRNAs in
human fetal brain during four gestation stages. (G) Expression of nine novel is-ncRNAs expression during fetal brain development, in three tumor cell
lines and in one clinical brain tumor sample. snRNA U6 served as an internal loading control.
doi:10.1371/journal.pone.0021652.g002
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rodents relative to other mammals. This is supported by the
overall tendency towards a higher conservation levels in the cow,
horse and dog genomes than in the rodents. As in the preceding
group, strong conservation is mostly limited to the primates, and
the average PhastCons score of these transcripts in other mammals
is generally below 0.6. Together with the transcripts only
conserved in primates, this group is enriched in loci with distinctly
differential expression in fetal tissues (Figure 2).
The third conservation group is a cluster of 14 loci that are well
conserved in the three primates included in the analysis (human,
chimpanzee and rhesus macaque), and a few loci showing either
conservation only between human and one of the primates (nc023,
nc028, nc046 and nc047) together with one transcript conserved
only in rodents (and possibly also chicken; nc044). A subgroup of
the primate-conserved transcripts include four loci (nc015, nc040,
nc063 and nc069) that are also conserved in at least one of the
rodents, but generally this cluster shows little conservation beyond
the primates.
To obtain a more complete view of the conservation state of the
novel is-ncRNAs in the primate lineage, we carried out a BlastN
on all the five primates for which genomic sequence data are
presently available (human, chimpanzee, orang-utan, rhesus
macaque and marmoset monkey; Figure S4). The BlastN data
show that the bulk of the novel transcripts is generally conserved
across the primate lineage. However, of the core ‘primate specific’
novel is-ncRNAs (i.e. those not even conserved in the rodents),
about half (5/11) of the loci are not conserved in the New World
marmoset monkey, suggesting that these loci have either appeared
in the Old World lineage after the split from the New World
monkeys or are too diverged to be identified by sequence
comparison. Pending the quality and completeness of the ape
genomes, the data also confirm that the nc028, nc044 and nc046
loci have arisen (or evolved quickly) in the human lineage, since
these three loci are not conserved in any of the two greater apes,
and each show possible conservation in only one of the two
monkey genomes.
is-ncRNA expression profile
The expressional characteristics of the 82 novel and the 244
known is-ncRNAs detected in the study were examined by
Northern blot and microarray analysis in several fetal tissues
(brain, heart, liver, lung and spleen), and during four stages of
human fetal brain development.
Expressional distribution of is-ncRNAs was studied in the fetal
tissue at the 24-week gestation stage. While the majority of both
known and novel transcripts showed only minor differences in
expression levels, more than one third (34) of the novel transcripts
showed distinct (i.e. .2-fold) differences in expression among
different tissues (figure 2A and Figure S5). These included
transcripts with distinctly elevated expression in a single tissue
(e.g. liver, nc030) or in two or more tissues (e.g. spleen and lung,
nc004), and transcript whose expression is strongly reduced in one
(e.g. nc071, spleen) or a few tissues (nc045). The expression of
transcript nc013 was investigated further by Northern blot
analysis, and was found absent in liver and thymus despite being
clearly expressed in an extended number of tissues (Figure 2C).
Relating expressional characteristics to conservation status sug-
gested a tendency towards novel ncRNA loci with strong
expressional variation across fetal tissues being less conserved
(i.e. conserved only in primates and/or a few other mammals) than
loci with more even expression patterns (Figure 2B).
Hierarchical clustering of the novel ncRNAs divided the
transcripts into two approximately equal groups with respect to
their expressional patterns. The first group (upper half of
Figure 2A) were composed of transcripts with some level of
expression in most tissues, whereas the second group suggested the
existence of several sub-groups of transcripts with expression
mainly limited to one or two tissues. These included one sub-group
comprised of 8 transcripts with predominant expression in the
heart, and an additional sub-group of 22 transcript with low
expression levels in most tissues other than heart or brain, along
with a third sub-group consisting of transcripts with predominant
expression in the brain.
Given the importance of the brain in human evolution, we were
particularly interested in ncRNAs with brain specific expression.
The microarray data indicated that the expression of a number of
both known and novel transcripts was higher in the fetal brain
than in other tissues (Figure S5). These included several snoRNAs
belonging to the imprinted HBII-52 cluster, which is known to be
highly expressed in mammalian brain and recently implicated in
the Prader-Willy syndrome pathology [23]. However, several
other annotated is-ncRNAs (e.g. snoRNAs U105B, U34 and U80)
which have previously not been reported as brain specific also
showed predominant or exclusive expression in the fetal brain at
the tested gestation stage. Of the novel ncRNAs with specific or
predominant expression in the fetal brain, we obtained Northern
blotting results across five tissues for 6 of the transcripts. Four of
these were only expressed in the fetal brain, whereas the two
remaining transcripts showed elevated expression in this tissue
(Figure 2D). The data thus strongly suggest that specific expression
of intermediate-size ncRNAs is an aspect of fetal human brain
development.
When all analysed is-ncRNAs (i.e. known and novel) are
compared, the expression levels of known loci generally appeared
to be higher than those of the novel loci, whereas the expressional
variation across tissues was more pronounced for the novel loci
(Figure S5). To the extent that known loci did show distinct
expressional variation across tissues, the majority of these showed
elevated expression in the brain relative to other tissues (e.g. the
HBII-52 series of snoRNAs). In total only 46 (19%) of the known
transcripts show more than 2-fold expressional variation between
tissues, compared to 41% of the novel transcripts. It thus appears
that previously known is-ncRNAs generally represent highly and
ubiquituously expressed noncoding loci, whereas the set of novel
transcripts obtained in our approach to a larger extent may
represent less abundant transcripts with a higher tendency
towards variable expression across different tissues. Hierarchical
clustering of all investigated transcripts produced a clustering
pattern with only partial resemblance to that observed for the
novel transcripts. Intriguingly, the clusters of novel transcripts
with predominant expression in the heart, or in heart and brain,
remained mostly intact when analysed along with previously
known transcripts, suggesting that these may represent previously
uninvestigated expression patterns of human is-ncRNAs. On the
other hand, the novel transcripts with predominant expression in
the fetal brain disperse among several clusters dominated by
known is-ncRNAs, possibly reflecting earlier efforts on mapping
such transcripts in the human or mammalian central nervous
system [38].
Figure 3. Conservation of 82 novel human is-ncRNA loci in 17 different vertebrates. The scale indicates average PhastCons score. As
indicated, most novel is-ncRNA loci could be broadly divided into three groups based on similar conservation characteristics.
doi:10.1371/journal.pone.0021652.g003
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ncRNAs across four gestation stages (13, 14, 20 and 24 weeks)
showed clear differences in fetal brain expression levels for at least
two of the transcripts (Figure 2G). Further analysis by microarray
showed various expression patterns across these four gestation
stages (Figure 2E). Only seven of the novel transcripts (8.5%)
displayed distinct (i.e. .2-fold) variation in their expression levels
through the course of the investigated period. However, when
contrasted with the expressional variation produced by the 245
known is-ncRNAs, of which only one transcript (snoRNA U14-5;
Figure S3) showed distinct expressional variation across the same
developmental period, this nonetheless suggests that the novel set
of is-ncRNA may be enriched in transcripts related to fetal brain
development. Given that the expressional analysis only includes
four time points over less than one-third of the gestation period,
and that many (,14) show very low expression throughout the
period, the novel set of is-ncRNAs might well contain an even
higher number of transcripts that are activated during other times
of fetal brain development.
The seven novel transcripts with distinctly differential expres-
sion levels across gestation stages display varying expression
patterns. Transcripts nc024 and nc061 show inclining expression
over the analysed period, peaking at week 24, whereas transcripts
nc005 and nc051 decline towards week 20, thereafter rising
sharply. The remaining three novel transcripts all show an
expression minimum at week 14, followed by increased expression
at the two later stages. The previously annotated snoRNA U14-5
is apparently activated at some stage after week 14, and show
strong expression in week 20 to 24. The seven novel transcripts are
with one exception (nc055) conserved in most placental mammals
(Table 1), which should allow for functional studies of homologues
of these transcripts in rodents or other mammals. The primate
specific nc055 is found in the genomes of all sequenced primates
apart from the marmoset, and a possible homologue also exists in
the horse genome. Three of the transcripts (nc005, nc024 and
nc055) show distinctly differential expression across tissues, but
only transcript nc051 shows brain specific expression (as verified
by Northern blot analysis), thus, their temporal activities may not
necessarily be restricted to fetal brain development.
In comparison to the novel transcripts, the known is-ncRNAs
were characterized by a generally higher overall expression level
in the fetal brain, while simultaneously a large number of the
transcripts showed very little (,1-fold) expressional variation
throughout the investigated period (Figure S6). The snoRNA
HBII-52 cluster loci, though not distinctly elevated at any stage,
showed a general tendency to higher expression towards the end
of the period, whereas the apparently brain-specific snoRNAs
U105B, U34 and U80 all show intermediate and very even
expression levels across the four gestation stages.
Ectopic expression of is-ncRNAs inhibited cancer cell
proliferation
Noncoding RNAs have been linked to tumor development in
several cases [39,40,41,42], and we therefore used Northern
blotting to examine the expression of nine novel is-ncRNAs in
three tumor cell lines and one clinical brain tumor sample. Five of
nine tested novel is-ncRNAs were not expressed in the
neuroblastoma cell line SH-SY5Y, and one was not expressed in
the glioma cell line U251 (Figure 2G). In contrast, the BE(2)-M17
neuroblastoma cells and the clinical tumor sample displayed
elevated expression of transcripts nc050 and nc029. Microarray
analysis of cell lines SH-SY5Y and U251 further indicated that
several known and novel transcripts showed strongly increased or
reduced expression (Figure S7).
Given the conspicuous absence of expression of several novel is-
ncRNAs in the cell lines, we speculated whether this lack of
expression might be directly related to cell vitality and prolifer-
ation. We therefore cloned 17 different novel is-ncRNA in the
lentiviral expression vector pSIH1-H1-Puro, and studied the
activity of SH-SY5Y cells after transfection with these vectors.
Seven of the novel is-ncRNAs that were selected for this study
were either predominantly expressed in brain (nc025, nc051,
nc073, nc075) or not expressed in SH-SY5Y (nc039), or had both
these expressional characteristics (nc018, nc035), whereas ten
transcripts were randomly selected among the novel clones (nc001,
nc005, nc017, nc019, nc058, nc062, nc067, nc070, nc077, nc079).
The SH-SY5Y cells were cultured for 72 hours after transfection,
and the effects on cell vitality were estimated using the MTS assay.
Cells transfected with three of the 17 is-ncRNAs showed
significantly reduced formazan concentration (53.6363.47%
decrease for nc039, 35.5964.64% decrease for nc070 and
34.9962.42% decrease for nc075, p,0.01, n=3) compared to
cells transfected with empty vector (Figure 4), and visual inspection
of these cell cultures indicated markedly reduced cell densities.
The reduction in cell activity was most pronounced in cells
transfected with nc039, which was one of the transcripts whose
expression was undetectable in the SH-SY5Y cell line, whereas
transcript nc070 and the brain specific nc075 appeared to reduce
cell activity to a lesser extent. Though preliminary, these data do
suggest that among the numerous deviating expressional patterns
observed in the carcinogenic cell lines, there may exist is-ncRNA
activity that pertains directly to the carcinogenic state of these
cells.
Discussion
Recent analysis have demonstrated that the central nervous
system is among the tissues most enriched in expressed miRNAs
[43] and long noncoding transcripts [1] in mammals. Though the
specific functions of most noncoding transcripts remain unknown,
it has been suggested that bridging the informational gap between
the analogue information of protein conformational space and the
digital information of the genome may be a particularly important
aspect of ncRNA function in the evolution and function of the
central nervous system [44]. In the present study, we have
obtained experimental evidence for 82 novel intermediate size
ncRNAs expressed in the fetal brain, and although these
transcripts do not constitute a large fraction of known human
transcripts in this size range, they nonetheless provide additional
insights into the noncoding transcriptome in the human fetal
brain.
Table 1. Seven novel is-ncRNAs showing distinct (.2-fold)
variation in expression across four gestation stages.
ID Conservation Tissue (.2-fold)
nc005 Placental mammals Heart (up)
nc008 Placental mammals Lung
nc024 Placental mammals Heart, spleen (up)
nc051 Placental mammals Brain
nc055 Primates Heart, brain (up)
nc061 Placental mammals All the tissues
nc078 Placental mammals All the tissues
doi:10.1371/journal.pone.0021652.t001
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which 75% were previously known (or predicted) transcripts. The
expression levels of known and novel is-ncRNAs, as estimated
from their clone numbers, were markedly different. Whereas a
majority of the previously known is-ncRNAs was detected as
multiple clones, most of the novel is-ncRNAs were detected as
single or few copy clones. Known transcripts are commonly
‘housekeeping’ types of is-ncRNAs with general functions (e.g.
splicing, RNA modification, etc) requiring relatively high expres-
sion levels in all or most cells. The novel is-ncRNAs, on the other
hand, are probably most transcripts that are expressed at either
lower overall levels or only in few cells or cell types, both
suggesting more specific functional repertoires.
As also apparent in this study, is-ncRNAs loci are commonly
found within the introns of protein coding genes, from which they
may either be released during pre-mRNA splicing, or be
transcribed from independent promoters [33]. Though intronic
is-ncRNA loci may not be functionally related to their host genes,
functional correlations are observed (e.g. snoRNAs are commonly
found within introns of genes coding for ribosomal proteins [33]).
The observation that host genes for the novel is-ncRNAs extracted
from human fetal brain displayed statistically significant enriched
in a cellular pathway related to neuronal development is thus
intriguing, in particular as several of the hosted loci were
preferentially expressed in fetal brain tissue or showed distinct
expressional variation during fetal brain development.
Close to one-fifth of the novel transcripts are not extensively
conserved beyond the primates, adding to the increasing number
of primate-specific ncRNAs detected in recent years [45].
Although the functional aspects of such transcripts are only slowly
being unravelled, there are already several indications of ncRNAs
being involved in central nervous system development activity.
The HAR1F RNA, transcribed from a highly conserved mamma-
lian locus showing rapid evolvement in the human lineage, has
been implicated in cortical development in human and chimpan-
zee [46].
The expressional characteristics of the detected is-ncRNAs were
further examined by Northern blot and microarray analysis. The
data showed distinct variations in expression levels for a subset of
the novel transcripts, including eight transcripts with predominant
expression in the fetal brain, and a larger group mostly expressed
in brain and heart. The quality of the microarray analysis was
corroborated by the fact that most is-ncRNAs known to be
expressed in the brain showed distinctly elevated expression in the
fetal brain relative to other tissues. The failure to clone the BC200
transcript probably owes to its internal A-rich tract, which lead to
its removal from the RNA extract along with the polyA-tailed
RNA fraction. The observation that a number of novel transcripts
cloned from fetal brain extracts nonetheless show predominant
expression in tissue other than the fetal brain, could be explained
by is-ncRNAs having positive functions in various tissues across a
wider range of expressional levels. It could also be that a given is-
ncRNA may have functions within a limited range of specific cell
types distributed among several tissues, thus appearing to occur at
relatively low levels in tissues where it is only expressed in a
minority of the cells or cell types constituting the tissue.
Though the expressional tissue specificity of the novel is-
ncRNAs did not strongly reflect their fetal brain origin from which
they were cloned, transcripts showing distinct changes in
expression levels during fetal brain development were relatively
more frequent among the novel is-ncRNAs (7 out of 82) than in
the collection of previously known transcripts (1 out of 244). The
functional relevance of the developmental changes in is-ncRNA
expression remains to be elucidated for both known and novel
transcripts, but it nonetheless demonstrates the potential of
focusing on this complement of the transcriptome for obtaining
further knowledge on neuronal development and function. An
especially intriguing case in this respect is represented by transcript
nc051 which in addition to its evolutionary constraints and
particular genomic location also display distinct variation during
fetal brain development. The single known transcript showing
distinct expressional variation through fetal development (snoRNA
U14-5) adds to the increasing number of snoRNA-like transcripts
apparently engaged in roles not readily explained by the mere
‘housekeeping’ modifications of rRNA, tRNA or snRNAs. The
involvement of snoRNA-like transcripts in CNS (central nervous
system) function is increasingly attracting attention. The comple-
ment of snoRNA-like transcripts in mammals and other
vertebrates [47] is much larger than can be accounted for by
the traditional roles of such transcripts in modification of rRNA,
tRNAs and snRNAs. The functional roles of these ‘orphan’
snoRNA-like transcripts are largely unknown, though snoRNA
involvement in the regulation of pre-mRNA splicing has been
demonstrated in one case concerning the imprinted HBII-52 locus
Figure 4. MTS assay of SH-SY5Y cells transfected with 17 different is-ncRNAs. MTS cell proliferation assay was carried out on day 3 after
lipofectamine transfection of SH-SY5Y cells with is-ncRNAs constructs or a mock vector as negative control. As indicated, cell populations transfected
with nc039, nc070 or nc075 construct had a significantly fewer number of metabolically active cells than cells transfected with a mock vector. The
data are expressed as three replicates in one experiment. Results represent those obtained in three experiments.
doi:10.1371/journal.pone.0021652.g004
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characteristics, and three of these were preferentially expressed in
brain, or brain and heart tissue.
The developmental expression analysis also provides additional
information on the expressional characteristics of previously
known and functionally described is-ncRNAs. The lack of
variation in expression of such transcripts during fetal develop-
ment is conspicuous, but might imply that the majority of these
perform constitutive roles in neuronal tissue that operate from
early stages of development. This might explain the relatively high
expression levels of some of these is-ncRNAs (e.g. the HBII-52
snoRNAs) and their early identification as brain-expressed
transcripts [24,38]. Alternatively, such transcripts might reach
their peak activity at developmental stages outside the temporal
range investigated in this study.
In addition to functions in brain evolution and development,
ncRNAs have been implicated in CNS disorders or malignancies.
MicroRNA-21 is highly expressed in glioma and targets various
genes involved in cell proliferation, migration and apoptosis
[15,49], and has been linked to glioma development [15,49]. On
the other hand, miR-124a, the most abundant miRNA in central
nervous system, has been reported to be down-regulated in high-
grade glial neoplasms and suppress glioma cell proliferation [50].
The Alu-derived BC200 ncRNA has long been studied for its
potential role in regulation of post-synaptic translation, possibly in
concert with the fragile X mental retardation protein [51], and
knock-down of its putative rodent analogue BC1 produces
behavioural deviations in mice [32]. BC200 also displays
expressional increases that correlates with spatial and progressive
severity of Alzheimer’s symptoms [52], and is overexpressed in a
number of non-neuronal malignancies [53]. The snoRNA-
encoding GAS5 has also been implicated in cancer development
[54]. Several of the novel is-ncRNAs were shown to be absent or
down-regulated in SH-SY5Y cells, as compared with normal brain
tissue, and restoration of three transcripts expression resulted in a
pronounced decrease in the cell numbers. Although this evidence
is still preliminary and incomplete, it does nonetheless imply that
these is-ncRNAs are involved in the cell proliferation process, and
possibly also associated with tumor development. Future research
on cause and maintenance of malignant cell states should focus
further on this specific complement of noncoding transcripts.
In summary, the novel is-ncRNAs reported in this study
represent an important early step in appreciating the significance
of ncRNAs in human brain biology. Moreover, our results not
only identify a number of ncRNAs that may be subjected to future
study, but also support the notion that some of these novel
transcripts are intrinsically functional and involved in brain
development and tumorigenesis.
Materials and Methods
Cell lines
Three human tumor cell lines, SH-SY5Y, BE(2)-M17 and
U251, were purchased from the Institute of Basic Medical
Sciences of the Chinese Academy of Medical Sciences. SH-
SY5Y cells were cultured in DMEM/F-12 1:1 (Invitrogen), and
the two other cell lines were cultured in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT) and L-glutamine at 37uC. All cells were
incubated at 37uC in a humidified incubator containing 5% CO2.
Ethics statement
We collected human fetal brain tissue from 5 gestational stages
(12 weeks, 13 weeks, 14 weeks, 20 weeks and 24 weeks) and human
fetal liver, spleen, heart and lung tissues at 24 weeks. Sample
collection was approved by the Wenzhou Medical College ethics
committee on research involving human subjects, and written
informed consent was obtained from the parents in each case. All
experiments were performed in compliance with the Helsinki
Declaration and national laws.
ncRNA library construction
The ncRNA libraries were constructed as previously described
[33]. Total RNA was isolated from the human fetal brain tissues
according to the Trizol (Invitrogen) protocol. 1 mg total RNA
from 4 different gestational stages (12 w, 14 w, 20 w, 24 w) was
pooled and mixed in equal aliquots, then the total RNA mix was
loaded on a Qiagen RNA/DNA maxi column (Qiagen). The
column was maintained at 50uC in a water bath and the RNA was
eluted on a 0.7–1.1 M NaCl gradient in QRV2 buffer (Qiagen
RNA/DNA Handbook). Each of the eluted fractions were
isopropanol precipitated with glycogen and 3 M NaAc (pH 5.2)
overnight at 220uC. The 0.9 and 1.0 M NaCl fractions
containing RNAs in the size range 50–500 nucleotides were
pooled. Poly(A)
+ RNA was removed using the Ambion poly(A)
purist MAG Kit (Ambion). rRNAs, U1 and U4 snRNAs were
removed using the MICROBExpress Kit (Ambion), as described
in the kit manuals. The purified RNA was dephosphorylated with
calf intestine alkaline phosphatase (CIAP, Fermentas) and ligated
to the 39 end adaptor oligonucleotide (see Supplementary
Materials S1) using T4 RNA ligase (Fermentas). The ligation
product was purified with Trizol and divided into two equal
aliquots. One aliquot was treated with T4 Polynucleotide kinase
(PNK, Fermentas) to phosphorylate the uncapped RNA species in
the sample, the other aliquot was treated with Tobacco acid
pyrophosphatase (TAP, Epicentre) to remove 59-end methyl-
guanosine caps from capped RNA species. After removal of the
enzyme, each aliquot was ligated to the 59 end adaptor
oligonucleotide. After each ligation step, excessive adaptors and
short fragments were cleaned up on a Qiagen RNAeasy mini elute
column (Qiagen). The final pool of small RNA was reverse-
transcribed (RT) with SuperScript III (SS III, Invitrogen) and 3RT
primer (complementary to the 39 adaptor oligonucleotide) at 50uC.
The cDNA was amplified by polymerase chain reaction (PCR)
using Platinum Taq (Invitrogen) with the 3RT and 5CD primers
(see Supplementary Materials S1) for 15 or 25 cycles (94uC 15 sec,
50uC 30 sec, 72uC 30 sec). The PCR products were purified with
the QIAquick PCR Purification Kit (Qiagen) and ligated into the
TOPO PCR 2.1 vector (Invitrogen). Transformation into E. coli
was performed with the Invitrogen ElectroMAX DH10BT1
electro transformation kit. About 25,000 clones were selected for
Sanger sequencing at the Beijing Genomics Institute.
Northern blotting
DIG-labeled RNA probes were in vitro transcribed from plasmid
DNA with the DIG RNA Labeling Kit SP6/T7 (Roche). Total
RNA were extracted from human fetal brain at 4 different
gestational stages (13 w, 14 w, 20 w, 24 w), from human fetal
liver, lung, spleen heart, thymus, kidney and eye at 24 weeks of
gestation, and from 3 tumor cell lines (SH-SY5Y, BE(2)-M17, and
U251). Total RNA was size-separated by 6% denaturing PAGE
gel electrophoresis, transferred onto a nylon membrane (Hybond-
N+; GE Healthcare), hybridized with the DIG-labeled RNA
probes in RNA EASY Hyb buffer (Roche) at 60uCt o6 8 uC
overnight, and then treated with Blocking and Washing Buffer
(Roche). After equilibration in detection buffer, blots were
incubated with the chemiluminescent substrate CDP-star and
ncRNAs in Human Fetal Brain
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probe was used as an internal control.
RT-PCR
To confirm the expression of some ncRNAs in human fetal
brain, RT-PCR was performed by the SuperScriptH III First-
Strand Synthesis System (Invitrogen), according to manufacturer’s
instructions. Specific primers were designed based on the
sequences for each ncRNA. The PCR reaction was first at 94uC
for 5 min. Thirty-five PCR cycles were performed with each cycle
at 94uC for 15 seconds, 55uC for 30 seconds, and 72uC for
60 seconds. The final cycle was run in additional 10 minutes at
72uC. The PCR products were electrophorezed on PAGE gels,
then stained with SYBR Gold nucleic acid gel stain (Invitrogen)
and were photographed under blue-light transilluminators. The
size of each PCR product was estimated using a standard 25 bp
DNA ladder. Negative controls were also run simultaneously to
achieve the accuracy of RT-PCR. Non-DNASE-treated samples
containing genomic DNA were used as a template. The RT step
was omitted in order to check DNASE-treated samples without
residual genomic DNA. Each of the RT-PCR products was
identified by DNA sequencing.
59 -and 39-RACE
Total fetal brain RNA was ligated to 39 and 59 adapters, and
then reverse transcribed (RT) using SuperScript III. 59-and 39-
RACE was performed by PCR amplification of the RT products,
with one primer designed specific to the ncRNA sequence and the
other primer corresponding to either the 5CD or 3RT adapter for
the 59- and 39-RACE, respectively.
Microarray sample preparation and hybridization
Human fetal brain tissues (13 w, 14 w, 20 w, 24 w) and fetal
liver, spleen, heart and lung tissues (24 weeks) were used in the
microarray analysis. Total RNA was dephosphorylated with calf
intestine alkaline phosphatase (Fermentas) and ligated to the same
39 adapter oligonucleotide that was used for library construction.
1 mg ligated RNA of each sample was used to create cRNA
according to the protocol of the Low RNA Input Linear
Amplification Kit (Agilent Technologies) with the minor modifi-
cation that the ligated ncRNAs were reverse transcribed using an
oligonucleotide complementary to the 39 adapter (T7P-3AD2) and
extended with a 59 end T7 promoter sequence extension. The
cRNA was purified with the mirVana miRNA isolation kit
(Ambion), and labeled with Cy3 (or Cy5) using the CyDye mono-
reactive NHS Esters kit (GE Healthcare). The labeled cRNA was
purified by Qiagen RNeasy Mini Kit (Qiagen).
The microarray slides were prehybridized at 42uC for 1 h and
hybridized at 42uC for 16 h. Microarrays were scanned using
Axon GenePix 4000B (Molecular Devices), and raw data were
quantified with the ImaGene 3.0 software.
Microarray design and analysis
Microarray probes of 50 nt average length were designed
against the 326 cloned and sequenced fetal brain ncRNAs. For
ncRNAs longer than 200 nt two different probes were designed. In
addition to probes against the 326 ncRNAs the microarray also
contained positive control probes that were used to estimate the
RNA hybridization efficiency. Each probe was printed in triplicate
on a microarray (CapitalBio Corporation). The microarray was
used to examine ncRNA expression in different fetal tissues and in
fetal brain at various gestation stages. The analyses were based on
the loop design method [55,56], in which all combinations of two
samples (from either different tissues of different gestations stages)
were simultaneously hybridized to a microarray, each of the two
samples labeled with a different fluorescent probe (Cy3 or Cy5).
The microarray data were normalized using standard global
media normalization [57]. Differential expression between tissues
and gestation stages were calculated as log2-ratio using a method
by Vinciotti et al. [57]. The data was hierarchically clustered based
on the average-linkage methods, using the Cluster software [58],
and visualized using TreeView [59].
MTS assay
The ncRNAs nc067, nc035, nc025, nc017, nc039, nc019,
nc073, nc070, nc005, nc051, nc075, nc001, nc058, nc077, nc062,
nc018 and nc079 were cloned between the BamHI and EcoRI
sites of the pSH1 vector (containing a puromycin resistance gene).
The recombinant constructs and a mock vector (self-ligated pSH1
vector without insert) were transfected into SH-SY5Y cells by
lipofectamine 2000 according to the manual. After 72 hours
culture, cell proliferation was measured using the CellTiter 96
AQueous assay kit (Promega) according to the manufacturer’s
instructions. Briefly, the CellTiter 96 AQueous One Solution
Reagent was added to each well before incubation at 37uC for
3 hours. Cell proliferation was assessed by absorbance at 490 nm
using a microtiter plate reader (Molecular Devices). The data were
analyzed using the Student’s t test. Statistical significance was
accepted at p , 0.05.
NCBI GenBank and GEO submission
The ncRNA sequence data in this study have been submitted to
GenBank under accession nos. HQ292100-HQ292181. All mi-
croarray data is MIAME compliant and the raw data have been
deposited in the Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/) with accession number GSE26196.
Supporting Information
Figure S1 Flow chart for the process of ncRNA identi-
fication in human fetal brain. Pipline of is-ncRNAs
identification and confirmation in human fetal brain as indicated
in the figure.
(TIF)
Figure S2 Northern blot analysis of 58 ncRNAs in
human fetal brain. As indicated, 58 is-ncRNAs identified in
human fetal brain were confirmed by Northern blot analysis. Most
of all have a single band within the expected size range. In some
case with multiple bands, at least one band within the expected
size range.
(TIF)
Figure S3 RT-PCR analysis of 31 ncRNAs in human
fetal brain. As indicated, RT-PCR products of 31 ncRNAs in
PAGE gels. RT+ indicated reaction with reverse transcriptase and
RT- indicated omission of reverse transcriptase from the reaction
to exclude the possible contamination by genomic DNAs. All the
RT-PCR products are within the expected size range.
(TIF)
Figure S4 BlastN sequence alignments of novel is-
ncRNAs in primate genomes. (A) Alignments of all novel is-
ncRNAs in primate genomes. (B) Alignments of ‘Primate specific’
novel is-ncRNAs in primate genomes.
(TIF)
Figure S5 Clustered expression profiles of is-ncRNAs in
different tissues. Expression patterns of 326 clustered ncRNAs
ncRNAs in Human Fetal Brain
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21652(the figure includes both novel and known ncRNAs) in human fetal
brain, liver, spleen, lung and heart tissues.
(TIF)
Figure S6 Clustered expression profiles of is-ncRNAs
during human fetal brain development. Expression patterns
of 326 clustered ncRNAs (the figure includes both novel and
known ncRNAs) during human fetal brain development.
(TIF)
Figure S7 Clustered expression profiles of is-ncRNAs in
tumor cell lines. Expression patterns of 326 clustered ncRNAs
(the figure includes both novel and known ncRNAs) in glioma cell
line U251 and neuroblastoma cell line SH-SY5Y, as compared
with normal brain tissue.
(TIF)
Table S1 Distribution of sequenced clones. Distribution of
sequenced library clones on different RNA species and categories.
Sequenced clone numbers and percentage of novel and known
ncRNAs are indicated in the table.
(DOC)
Table S2 Genomic location of the novel ncRNA genes.
The length and chromosome location of all the novel ncRNAs are
presented in the table.
(DOC)
Table S3 Novel ncRNAs involved in axon guidance
pathway. Four ncRNAs, their host genes and annotations are
shown in the table.
(DOC)
Table S4 Predicted snoRNAs or scaRNAs of novel
ncRNAs. Fourteen ncRNAs with clear snoRNA or scaRNA
characteristics were identified. As indicated, four ncRNAs were
identified as C/D box snoRNAs, nine as H/ACA box snoRNAs,
and one transcript (nc089) which showed both C/D box and H/
ACA box characteristics is a likely scaRNA candidate.
(DOC)
Supplementary Materials S1 Oligos used and all novel
ncRNA sequences.
(DOC)
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